地诺单抗治疗骨巨细胞瘤后的恶性转化：一例报告
Malignant Transformation of a Giant Cell Tumor of Bone Treated with Denosumab: A Case Report.
作者信息
Park Andrew, Cipriano Cara A, Hill Kirk, Kyriakos Michael, McDonald Douglas J
机构信息
Departments of Orthopaedic Surgery (A.P., C.A.C., and D.J.M.) and Pathology (K.H. and M.K.), Washington University School of Medicine, St. Louis, Missouri.
出版信息
JBJS Case Connect. 2016 Jul-Sep;6(3):e78. doi: 10.2106/JBJS.CC.16.00024.
CASE
Giant cell tumor (GCT) of bone was first described almost 200 years ago, but the optimal treatment continues to evolve. We present a patient with a pelvic GCT who was treated with embolization, 20 months of denosumab therapy, and resection. Histologically, the tumor consisted of degenerated GCT, bone, and fibrous tissue. After 7 months, the patient was found to have osteosarcoma at the site of the initial lesion as well as pulmonary metastases.
CONCLUSION
The apparent malignant transformation of a GCT of bone treated initially with denosumab indicates that close follow-up is warranted.
病例
骨巨细胞瘤（GCT）在近200年前首次被描述，但最佳治疗方法仍在不断发展。我们报告一名骨盆骨巨细胞瘤患者，接受了栓塞治疗、20个月的地诺单抗治疗以及手术切除。组织学检查显示，肿瘤由退变的骨巨细胞瘤、骨和纤维组织组成。7个月后，患者在初始病变部位被发现患有骨肉瘤以及肺转移。
结论
最初用地诺单抗治疗的骨巨细胞瘤出现明显的恶性转化，这表明有必要进行密切随访。
Zotero 插件